

SCOPE: ALS, CCT	
MEDICATION:	TRANEXAMIC ACID (TXA)
INTERVENTION:	<p><u>Classification:</u> Antifibrinolytic Agent, Hemostatic Agent</p> <p><u>Actions:</u> Used to treat or prevent excessive blood loss by prevention of clot lysis</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Administration >3 hours post-injury • Isolated head/spinal injury • Extremity amputation with controlled bleeding and a strong expectation for re-implantation <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Breast-feeding: small amounts are excreted into breast milk • PREGNANCY RISK FACTOR: B (crosses the placenta) <p><u>Dosage:</u></p> <ol style="list-style-type: none"> I. Hemorrhagic Shock <ol style="list-style-type: none"> a. Adult: <ol style="list-style-type: none"> i. IV/IO: 1gm in 100 ml NS/LR, over 10 minutes and if available followed by infusion of 1gm in 250ml NS/LR over 8 hours (31.25ml/hr) b. Pediatric less than 14 years old or 100 lbs: <ol style="list-style-type: none"> i. IV/IO: 10 mg/kg in 100 ml NS/LR over 10 minutes (max 1 g) <p><u>Onset of Action:</u> Peak 1-5 hours (Average 2.5 hours)</p> <p><u>Duration:</u> 2-11 hours</p> <p><u>Adverse Effects:</u> Hypersensitivity reaction or ocular effects, seizure, thrombotic events, ureteral obstruction, CNS depression</p> <p><u>Special Considerations:</u></p> <ol style="list-style-type: none"> I. Hypotension may occur with rapid IV infusion

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 1